Comparison of the diagnostic efficacy of <sup>68</sup> Ga-FAPI-04 PET/MR and <sup>18</sup>F-FDG PET/CT in patients with pancreatic cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 35243518.
- Also identified by DOI 10.1007/s00259-022-05729-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We sought to assess the performance of <sup>68</sup> Ga-FAPI-04 PET/MR for the diagnosis of primary tumours as well as metastatic lesions in patients with pancreatic cancer and to compare the results with those of <sup>18</sup>F-FDG PET/CT. Prospectively, we evaluated 33 patients suspected to have pancreatic adenocarcinoma, of whom thirty-two were confirmed by histopathology, and one had autoimmune pancreatitis confirmed by needle biopsy and glucocorticoid treatment. Within 1 week, each patient underwent both <sup>68</sup> Ga-FAPI-04 PET/MR and <sup>18</sup>F-FDG PET/CT. Comparisons of the detection abilities for primary tumours, lymph nodes, and metastases were conducted for the two imaging approaches. The original maximum standard uptake values (SUV<sub>max</sub>) and normalised SUV<sub>max</sub> (SUV<sub>max</sub>/SUV<sub>bkgd</sub>) of paired lesions on <sup>68</sup> Ga-FAPI-04 PET/MR and <sup>18</sup>F-FDG PET/CT were measured and compared. Thirty pancreatic cancer patients and three pancreatitis patients were enrolled. <sup>68</sup> Ga-FAPI-04 PET/MR and <sup>18</sup>F-FDG PET/CT exhibited equivalent (100%) detection rates for primary tumours. The original/normalised SUV<sub>max</sub> of primary tumours on <sup>68</sup> Ga-FAPI-04 PET was markedly higher than that on <sup>18</sup>F-FDG (p < 0.05). Sixteen pancreatic cancer patients had pancreatic parenchymal uptake, whereas <sup>18</sup>F-FDG PET images showed parenchymal uptake in only four patients (53.33% vs. 13.33%, p < 0.001). <sup>68</sup> Ga-FAPI-04 PET detected more positive lymph nodes than <sup>18</sup>F-FDG PET (42 vs. 30, p < 0.001), while <sup>18</sup>F-FDG PET was able to detect more liver metastases than <sup>68</sup> Ga-FAPI-04 (181 vs. 104, p < 0.001). In addition, multisequence MR imaging helped explain ten pancreatic cancers that could not be definitively revealed due to <sup>68</sup> Ga-FAPI-04 inflammatory uptake and identified more liver metastases than <sup>18</sup>F-FDG (256 vs. 181, p < 0.001). <sup>68</sup> Ga-FAPI-04 PET might be better than <sup>18</sup>F-FDG PET in the detection of suspicious lymph node metastases. MR multiple sequence imaging of <sup>68</sup> Ga-FAPI-04 PET/MR was helpful for explaining pancreatic lesions in patients with obstructive inflammation and detecting tiny liver metastases.
Medical subject headings
- Adenocarcinoma
- Liver Neoplasms
- Pancreatic Neoplasms